Polyamine Sulfonamides for Selective AML Cell Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are ineffective, with refractory cases accounting for 80% of patient deaths and existing chemotherapy being highly toxic, causing significant side effects and being costly, highlighting the need for new antineoplastic agents.
Innovation Solution
Development of novel polyamine sulfonamides through a human AML-BMEC co-culture assay for high-throughput screening, which are selectively toxic to AML cells and inhibit alpha-enolase activity, leading to apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy agents (cytarabine, doxorubicin, daunorubicin, idarubicin) are used to treat AML, then some patients respond initially, but the treatment causes life-threatening side effects in 80% of patients and kills 10-20% of patients
Solution Approach 1:
The patent segments the treatment approach by using a co-culture assay system that separates AML cells from normal bone marrow cells, allowing selective identification of compounds toxic to AML cells while sparing normal cells. This segmentation enables differentiation between therapeutic effect and toxicity based on cell-type specificity.
Solution Approach 2:
The patent applies local quality by developing compounds with selective toxicity - the polyamine sulfonamides exhibit preferential killing of AML cells while having minimal effect on normal bone marrow cells. This localized selective action reduces systemic toxicity while maintaining antineoplastic effectiveness.
2Reliability
If high-throughput screening of 30 million compounds is performed using combinatorial chemistry, then novel selective agents are discovered, but the complexity and cost of drug development increase
Solution Approach 1:
The patent implements nesting by incorporating AML cells within a co-culture system that includes bone marrow stromal cells and endothelial cells. This nested cellular architecture allows the assay to screen for compounds that selectively kill AML cells while preserving the microenvironment, thereby identifying agents with true selective toxicity.
Solution Approach 2:
The patent uses an intermediary co-culture assay system as a mediator between compound screening and efficacy evaluation. This intermediary system provides a more physiologically relevant model than isolated cell cultures, enabling better prediction of in vivo selectivity without requiring complex animal models at each screening stage.
3Adaptability or versatility
If current AML treatment protocols are maintained, then standard care is provided, but refractory cases account for 80% of patient deaths and treatment costs run into billions of dollars annually
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of polyamines to create sulfonamide derivatives with improved pharmacological properties. These structural parameter changes result in compounds that maintain antineoplastic activity while reducing toxicity, thereby expanding effective treatment options for AML.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyamine sulfonamides demonstrate selective toxicity to AML cells, potentially offering a more effective and less toxic treatment option for AML and other hematological cancers by inducing apoptosis and modulating alpha-enolase activity.
Implementation Method 1
inhibit alpha-enolase activity
Data Source
AI summary
Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.